HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Consun Pharmaceutical (1681HK)- High-Priced Acquisition & Good Performance Show Big Upside Potential

Pre-IPO Weimeizi (Guangdong) - The Market Position Is Not Solid

Pre-IPO Rainmed Medical - The Industry, the Business and the Concerns

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Capital Markets

Shanghai Pulse Medical Technology / Equity Capital Markets

Shanghai Pulse Medical Technology (PMT HK)

<ul>
<li>The products of <a href="https://www.smartkarma.com/entities/shanghai-pulse-medical-technology" target="_blank" data-smartkarma-citation="entities:35581:1" rel="noopener">Shanghai Pulse Medical Technology (PMT HK)</a> have entered the commercialization stage, indicating that the Company has gone through the stage from 0 to 1.</li>
<li>The medical insurance coverage and CE Mark offer Pulse more options in terms of commercialization, which is very vital especially in front of domestic policy risk and unfriendly financing environment.</li>
<li>Next, Pulse needs to focus more on how to increase the market penetration, so as to present promising commercialization results. Overall, we are looking forward to the future of Pulse.</li>
</ul>


The products of Shanghai Pulse Medical Technology (PMT HK) have entered the commercialization stage, indicating that the Company has gone through the stage from 0 to 1.
The medical insurance coverage and CE Mark offer Pulse more options in terms of commercialization, which is very vital especially in front of domestic policy risk and unfriendly financing environment.
Next, Pulse needs to focus more on how to increase the market penetration, so as to present promising commercialization results. Overall, we are looking forward to the future of Pulse.


Pre-IPO Shanghai Pulse Medical Technology - The Industry, the Business and the Concerns